Answers are grounded in this paper and cite their sources.
Atopic dermatitis (AD) is a common, chronic inflammatory disease that affects millions of individuals worldwide. It is characterized by intense itching, recurrent eczematous lesions, and a relapsing-remitting course, all of which significantly impair quality of life. Conventional treatments, including topical corticosteroids, calcineurin inhibitors, and systemic immunosuppressants, often provide only partial relief or carry risks of adverse effects with prolonged use. The limited efficacy and safety concerns associated with existing therapies have driven interest in targeted approaches that address the underlying immune dysregulation. One such strategy involves inhibition of the Janus kinase (JAK)–signal transducer and activator of transcription (STAT) pathway, which plays a key role in transmitting inflammatory cytokine signals involved in AD pathogenesis. Upadacitinib, a selective JAK1 inhibitor initially approved for immune-mediated conditions such as rheumatoid arthritis and inflammatory bowel disease, has recently gained approval for moderate-to-severe AD, representing a promising addition to the list of current treatment options.
No takes yet. Share an insight, caveat, or question.
Shamim et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: